Table 4. Drugs Class/Agent
Oral Anticoagulants Antiplatelet Aspirin
Clopidogrel VKAs
Warfarin (Coumadin® Jantoven®
) Direct thrombin inhibitor
Dabigatran (Pradaxa®
PO ) Factor Xa Inhibitor
Rivaroxaban (Xarelto®
)
Injectables Anticoagulants Heparin (UFH)
LMWH
Enoxaparin (Lovenox®
)
Subcut, (IV)
FDA-approved for prophylaxis and treatment of DVT, prophylaxis of ischemic complications of unstable angina and non–Q-wave MI, and treatment of acute STEMI
Dalteparin (Fragmin®
Subcut )
Full deep venous thrombosis (DVT) treatment doses
Tinzaparin (Innohep®
) Subcut
FDA-approved for prophylaxis of DVT, prophylaxis of ischemic complications of unstable angina and non–Q-wave MI, and extended treatment of symptomatic venous thromboembolism in patients with cancer
FDA-approved for the treatment of acute symptomatic DVT with or without pulmonary embolism when administered in conjunction with warfarin sodium
5
PO with the evening meal
CrCl > 50 mL/min: 20 mg once daily CrCl 15-50 mL/min: 15 mg once daily
FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF (approved aſter submission of the guidelines)
IV Adjust to APTT
CrCl > 15 mL/min: 150 mg bid CrCl 15-30 mL/min: 75 mg bid
FDA-approved to reduce the risk of stroke and systemic embolism in patients with nonvalvular AF
PO , Adjust to INR
Route
Dose
Comments
PO PO
75-325 mg once daily 75 mg once daily
(Br
and)
